From susceptibility to prognosis: the multifaceted role of the cytochrome p450 family in hepatocellular carcinoma

Abstract

Abstract: The cytochrome P450 (CYP450) family is a group of enzymes that play a crucial role in the metabolism of exogenous and endogenous compounds. Growing evidence suggests that the CYP450 family is pivotal in the occurrence, progression, and prognosis of hepatocellular carcinoma (HCC). Polymorphisms in CYP450 family genes can influence an individual's susceptibility to carcinogens and metabolic capacity, closely associated with the risk of HCC. Furthermore, dysregulation of CYP450 family genes is involved in HCC progression, with mechanisms encompassing reactive oxygen species levels, DNA damage, cell proliferation, invasion, and apoptosis. The expression levels of CYP450 family genes are also intimately linked to the prognosis of HCC patients, showing promise as essential indicators for prognostic assessment. In conclusion, a deep understanding of the role of the CYP450 family in the occurrence, progression, and prognosis of HCC is of great significance for elucidating the molecular mechanisms of HCC and developing individualized prevention and treatment strategies. Future research should further investigate the molecular mechanisms underlying the polymorphisms and dysregulation of CYP450 family genes, establish corresponding risk prediction and prognostic evaluation models, and emphasize the regulatory effects of drugs on the CYP450 family, aiming to provide new strategies and targets for the prevention and treatment of HCC.

Key words: Cytochrome P450, Hepatocellular carcinoma, Gene polymorphism, Metabolism, Prognosis

Hong Shengjie, Zhang Guangquan, Li Ruixi, He Yongfei, Wu Fenfang, Shi Xianjie. From susceptibility to prognosis: the multifaceted role of the cytochrome p450 family in hepatocellular carcinoma[J]. Electronic Journal of Liver Tumor, 2024, 11(3): 58-63.

References

[1] BRAY F, LAVERSANNE M, SUNG H, et al.Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.
[2] 郑荣寿,陈茹,韩冰峰,等. 2022年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2024,46(3):221-231.
[3] Nelson D R, Koymans L, Kamataki T, et al.P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature[J]. Pharmacogenetics, 1996, 6(1): 1-42.
[4] ZANGER U M, SCHWAB M.Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation[J]. Pharmacol Ther, 2013, 138(1): 103-141.
[5] LIM S, ALSHAGGA M, ONG C E, et al.Cytochrome P450 4B1 (CYP4B1) as a target in cancer treatment[J]. Hum Exp Toxicol, 2020, 39(6): 785-796.
[6] SNEHA S, BAKER S C, GREEN A, et al.Intratumoural cytochrome P450 expression in breast cancer: impact on standard of care treatment and new efforts to develop tumour-selective therapies[J]. Biomedicines, 2021, 9(3): 290.
[7] ELZAKI M E A, XUE R R, HU L, et al. Bioactivation of aflatoxin B1 by a cytochrome P450, CYP6AE19 induced by plant signaling methyl jasmonate in Helicoverpa armigra (Hübner)[J]. Pestic Biochem Physiol, 2019, 157: 211-218.
[8] SILVESTRI L, SONZOGNI L, DE SILVESTRI A, et al.CYP enzyme polymorphisms and susceptibility to HCV-related chronic liver disease and liver cancer[] [J]. Int J Cancer, 2003, 104(3): 310-317.
[9] IMAIZUMI T, HIGAKI Y, HARA M, et al.Interaction between cytochrome P450 1A2 genetic polymorphism and cigarette smoking on the risk of hepatocellular carcinoma in a Japanese population[J]. Carcinogenesis, 2009, 30(10): 1729-1734.
[10] CHEN X, WANG H, XIE W, et al.Association of CYP1A2 genetic polymorphisms with hepatocellular carcinoma susceptibility: a case-control study in a high-risk region of China[J]. Pharmacogenet Genomics, 2006, 16(3): 219-227.
[11] RAUNIO H, JUVONEN R, PASANEN M, et al.Cytochrome P4502A6 (CYP2A6) expression in human hepatocellular carcinoma[J]. Hepatology, 1998, 27(2): 427-432.
[12] RAUNIO H, RAUTIO A, GULLSTÉN H, et al. Polymorphisms of CYP2A6 and its practical consequences[J]. Br J Clin Pharmacol, 2001, 52(4): 357-363.
[13] ZHENG D, WANG X, ANTONSON P, et al.Genomics of sex hormone receptor signaling in hepatic sexual dimorphism[J]. Mol Cell Endocrinol, 2018, 471: 33-41.
[14] Ren J, Chen GG, Liu Y, et al. Cytochrome P450 1A2 Metabolizes 17β-Estradiol to Suppress Hepatocellular Carcinoma. PLoS One, 2016, 11(4): e0153863. Published 2016 Apr 19.
[15] 李艳敏,李翠翠,郑航,等.雌激素通过ER-α调控CYP2C8在鸡肝中的表达[J].畜牧兽医学报,2016,47(12):2362-2369.
[16] JI F, ZHANG J, LIU N, et al.Blocking hepatocarcinogenesis by a cytochrome P450 family member with female-preferential expression[J]. Gut, 2022, 71(11): 2313-2324.
[17] TANAKA S, MOGUSHI K, YASEN M, et al.Oxidative stress pathways in noncancerous human liver tissue to predict hepatocellular carcinoma recurrence: a prospective, multicenter study[J]. Hepatology, 2011, 54(4): 1273-1281.
[18] SCIARRA A, PINTEA B, NAHM J H, et al.CYP1A2 is a predictor of HCC recurrence in HCV-related chronic liver disease: a retrospective multicentric validation study[J]. Dig Liver Dis, 2017, 49(4): 434-439.
[19] REN X, JI Y, JIANG X, et al.Downregulation of CYP2A6 and CYP2C8 in tumor tissues is linked to worse overall survival and recurrence-free survival from hepatocellular carcinoma[J]. Biomed Res Int, 2018, 2018: 5859415.
[20] LI C, ZHOU D, JIANG X, et al.Identifying hepatocellular carcinoma-related hub genes by bioinformatics analysis and CYP2C8 is a potential prognostic biomarker[J]. Gene, 2019, 698: 9-18.
[21] AWAN F M, NAZ A, OBAID A, et al.Identification of circulating biomarker candidates for hepatocellular carcinoma (HCC): an integrated prioritization approach[J]. PLoS One, 2015, 10(9): e0138913.
[22] FAN W, YE G.Microarray analysis for the identification of specific proteins and functional modules involved in the process of hepatocellular carcinoma originating from cirrhotic liver[J]. Mol Med Rep, 2018, 17(4): 5619-5626.
[23] SHUAICHEN L, GUANGYI W.Bioinformatic analysis reveals CYP2C9 as a potential prognostic marker for HCC and liver cancer cell lines suitable for its mechanism study[J]. Cell Mol Biol (Noisy-le-grand), 2018, 64(7): 70-74.
[24] HO J C, CHEUNG S T, LEUNG K L, et al.Decreased expression of cytochrome P450 2E1 is associated with poor prognosis of hepatocellular carcinoma[J]. Int J Cancer, 2004, 111(4): 494-500.
[25] ASHIDA R, OKAMURA Y, OHSHIMA K, et al.CYP3A4 gene is a novel biomarker for predicting a poor prognosis in hepatocellular carcinoma[J]. Cancer Genomics Proteomics, 2017, 14(6): 445-453.
[26] LI D, YU T, HU J, et al.Downregulation of CYP39A1 serves as a novel biomarker in hepatocellular carcinoma with worse clinical outcome[J]. Oxid Med Cell Longev, 2021, 2021: 5175581.
[27] ASHIDA R, OKAMURA Y, OHSHIMA K, et al.The down-regulation of the CYP2C19 gene is associated with aggressive tumor potential and the poorer recurrence-free survival of hepatocellular carcinoma[J]. Oncotarget, 2018, 9(31): 22058-22068.
[28] JIANG F, CHEN L, YANG Y C, et al.CYP3A5 Functions as a tumor suppressor in hepatocellular carcinoma by regulating mTORC2/Akt signaling[J]. Cancer Res, 2015, 75(7): 1470-1481.
[29] XIAO Y, YU D.Tumor microenvironment as a therapeutic target in cancer[J]. Pharmacol Ther, 2021, 221: 107753.
[30] JIANG T, ZHU A S, YANG C Q, et al.Cytochrome P450 2A6 is associated with macrophage polarization and is a potential biomarker for hepatocellular carcinoma[J]. FEBS Open Bio, 2021, 11(3): 670-683.
[31] ÖZKAN A, STOLLEY D L, CRESSMAN E N K, et al. Vascularized hepatocellular carcinoma on a chip to control chemoresistance through cirrhosis, inflammation and metabolic activity[J]. Small Struct, 2023, 4(9): 2200403.
[32] LIANG H C, LI H, MCKINNON R A, et al.Cyp1a2(-/-) null mutant mice develop normally but show deficient drug metabolism[J]. Proc Natl Acad Sci U S A, 1996, 93(4): 1671-1676.
[33] LANGOUËT S, COLES B, MOREL F, et al. Inhibition of CYP1A2 and CYP3A4 by oltipraz results in reduction of aflatoxin B1 metabolism in human hepatocytes in primary culture[J]. Cancer Res, 1995, 55(23): 5574-5579.
[34] LOOTENS O, DE BOEVRE M, GASTHUYS E, et al.Unravelling the pharmacokinetics of aflatoxin B1: In vitro determination of Michaelis-Menten constants, intrinsic clearance and the metabolic contribution of CYP1A2 and CYP3A4 in pooled human liver microsomes[J]. Front Microbiol, 2022, 13: 988083.
[35] RAUNIO H, RAHNASTO-RILLA M.CYP2A6: genetics, structure, regulation, and function[J]. Drug Metabol Drug Interact, 2012, 27(2): 73-88.
[36] LI J, HUSSAIN Z, ZHU J, et al.Role of CYP2A6 in methimazole bioactivation and hepatotoxicity[J]. Chem Res Toxicol, 2021, 34(12): 2534-2539.
[37] TANG W, CHEN Z, ZHANG W, et al.The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects[J]. Signal Transduct Target Ther, 2020, 5(1): 87.
[38] SONG H Y, XIA J S, CHEN Y G, et al.Cytochrome P450 3A5 polymorphism affects the metabolism of sorafenib and its toxicity for hepatocellular carcinoma cells in vitro[J]. Hum Exp Toxicol, 2022, 41: 9603271221080236.
[39] YU J, WANG N, GONG Z, et al.Cytochrome P450 1A2 overcomes nuclear factor kappa B-mediated sorafenib resistance in hepatocellular carcinoma[J]. Oncogene, 2021, 40(3): 492-507.
[40] ZHOU X, LI T M, LUO J Z, et al.CYP2C8 suppress proliferation, migration, invasion and sorafenib resistance of hepatocellular carcinoma via PI3K/Akt/p27kip1 axis[J]. J Hepatocell Carcinoma, 2021, 8: 1323-1338.
[41] JIANG F, CHEN L, YANG Y C, et al.CYP3A5 Functions as a tumor suppressor in hepatocellular carcinoma by regulating mTORC2/Akt signaling[J]. Cancer Res, 2015, 75(7): 1470-1481.
[42] YU J, XIA X, DONG Y, et al.CYP1A2 suppresses hepatocellular carcinoma through antagonizing HGF/MET signaling[J]. Theranostics, 2021, 11(5): 2123-2136.
[43] 朱利利. CYP1A2通过ROS调控Gsk3β-Axin-JNK信号轴抑制肝癌细胞增殖与侵袭[D].郑郑州:州大学,2021.
[44] YAN Q G, SHI J G, ZHANG F, et al.Overexpression of CYP2E1 enhances sensitivity of hepG2 cells to fas-mediated cytotoxicity[J]. Cancer Biol Ther, 2008, 7(8): 1280-1287.
[45] YANG H, NIE Y, LI Y, et al.Histone modification-mediated CYP2E1 gene expression and apoptosis of HepG2 cells[J]. Exp Biol Med (Maywood), 2010, 235(1): 32-39.
[46] ZHU L, YANG X, FENG J, et al.CYP2E1 plays a suppressive role in hepatocellular carcinoma by regulating Wnt/Dvl2/β-catenin signaling[J]. J Transl Med, 2022, 20(1): 194.
[47] LIU H, LOU G, LI C, et al.HBx inhibits CYP2E1 gene expression via downregulating HNF4α in human hepatoma cells[J]. PLoS One, 2014, 9(9): e107913.
[48] DIESINGER T, LAUTWEIN A, BERGLER S, et al.A New CYP2E1 inhibitor, 12-imidazolyl-1-dodecanol, represents a potential treatment for hepatocellular carcinoma[J]. Can J Gastroenterol Hepatol, 2021, 2021: 8854432.
[49] ISHTEYAQUE S, YADAV K S, VERMA S, et al.CYP2E1 triggered GRP78/ATF6/CHOP signaling axis inhibit apoptosis and promotes progression of hepatocellular carcinoma[J]. Arch Biochem Biophys, 2023, 745: 109701.
[50] SHEN H, WU H, SUN F, et al.A novel four-gene of iron metabolism-related and methylated for prognosis prediction of hepatocellular carcinoma[J]. Bioengineered, 2021, 12(1): 240-251.
[51] LI J, JIA Y C, DING Y X, et al.The crosstalk between ferroptosis and mitochondrial dynamic regulatory networks[J]. Int J Biol Sci, 2023, 19(9): 2756-2771.
[52] TU D Y, CAO J, ZHOU J, et al.Identification of the mitophagy-related diagnostic biomarkers in hepatocellular carcinoma based on machine learning algorithm and construction of prognostic model[J]. Front Oncol, 2023, 13: 1132559.
[53] UTGIKAR R, RIDDICK D S.Downregulation of cytochrome P450 2C8 by 3-methylcholanthrene in human hepatocellular carcinoma cell lines[J]. Can J Physiol Pharmacol, 2017, 95(6): 768-771.
[54] 张绮悦,杨长青.食物、中药及其有效成分单体对CYP2C8的抑制作用研究进展[J].中国当代医药,2020,27(24):33-36.